Amiodarone - sanofi-aventis

Drug Profile

Amiodarone - sanofi-aventis

Alternative Names: Amiodarone IV; Ancaron

Latest Information Update: 17 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taisho Pharmaceutical
  • Developer Sanofi
  • Class Benzofurans; Class III antiarrhythmics; Heart failure therapies; Small molecules
  • Mechanism of Action Beta-adrenergic receptor antagonists; Calcium channel antagonists; KATP channel inhibitors; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Atrial fibrillation

Highest Development Phases

  • Marketed Ventricular arrhythmias

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 05 Sep 2007 Data presented at the European Society of Cardiology Congress 2007 (ESC-2007) added to the Arrhythmias pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top